Stockscreener 앱 받기
17.23
0.29%
0.05
시간 외 거래:
17.50
0.27
+1.57%
전일 마감가:
$17.18
열려 있는:
$17.22
하루 거래량:
36,352
Relative Volume:
0.57
시가총액:
$124.23M
수익:
$100.44M
순이익/손실:
$-133.16M
주가수익비율:
-0.6689
EPS:
-25.76
순현금흐름:
$-94.85M
1주 성능:
-3.31%
1개월 성능:
+28.01%
6개월 성능:
+114.84%
1년 성능:
+75.64%
1일 변동 폭
$17.12
$17.80
1주일 범위
$16.65
$18.25
52주 변동 폭
$5.005
$18.70
아타라 Stock (ATRA) Company Profile
명칭
Atara Biotherapeutics Inc
전화
805-623-4211
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
ATRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
17.23 | 123.87M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
아타라 Stock (ATRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-09 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-20 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-07-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-05-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 개시 | Evercore ISI | Outperform |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-09-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-06-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-05-23 | 개시 | Stifel | Buy |
| 2019-01-23 | 개시 | Mizuho | Buy |
| 2018-04-10 | 개시 | JP Morgan | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2018-03-05 | 재확인 | Jefferies | Buy |
| 2018-02-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-01-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
아타라 주식(ATRA)의 최신 뉴스
Is Atara Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 Retail & Real-Time Volume Analysis Alerts - Улправда
(ATRA) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Is Atara's Tab-Cel The Missing Piece In A Difficult-To-Treat Cancer? - RTTNews
Panic Selling: Why Atara Biotherapeutics Inc stock could be next big winner2025 Buyback Activity & Fast Momentum Stock Entry Tips - moha.gov.vn
Atara Biotherapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Would You Still Hold Atara Biotherapeutics Stock If It Fell Another 30%? - Trefis
Can Atara Biotherapeutics Stock Recover If Markets Fall? - Trefis
How Atara Biotherapeutics Inc. stock performs during Fed tightening cyclesWeekly Investment Report & Weekly Watchlist of Top Performers - Newser
Can Atara Biotherapeutics Inc. (AT20) stock hit consensus price targetsJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is Atara Biotherapeutics Inc. (AT20) stock trading at attractive multiplesJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - Newser
Why Atara Biotherapeutics Inc. (AT20) stock gets analyst attentionPortfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Is Confidence Futuristic Energetech Limited a Top Alpha Generator for Growth PortfoliosMarket Correction Analysis & Free Real-Time Trading Signals - earlytimes.in
Can Atara Biotherapeutics Inc. stock maintain operating margins2025 Key Lessons & Reliable Breakout Forecasts - Newser
Atara Biotherapeutics (ATRA) Stock Analysis Report | Financials & Insights - Benzinga
Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
Why Atara Biotherapeutics Inc. (AT20) stock could rally strongly2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
How robust is Atara Biotherapeutics Inc. (AT20) stock financial positionPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - Newser
Why analysts remain bullish on Atara Biotherapeutics Inc. stockTrade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Can Atara Biotherapeutics Inc. (AT20) stock sustain revenue momentum2025 Trading Recap & Free Long-Term Investment Growth Plans - Newser
Is Atara Biotherapeutics Inc. stock attractive for long term wealth buildingQuarterly Risk Review & Expert Verified Movement Alerts - Newser
Will Atara Biotherapeutics Inc. (AT20) stock benefit from infrastructure billJuly 2025 PostEarnings & Verified Short-Term Plans - Newser
Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA) - Seeking Alpha
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) (PR Newswire) - Aktiellt
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. (PR Newswire) - Aktiellt
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Target Price from Analysts - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Understanding the Setup: (ATRA) and Scalable Risk - news.stocktradersdaily.com
Mizuho raises Atara Biotherapeutics stock price target on reduced expenses By Investing.com - Investing.com Canada
Atara Biotherapeutics Inc Stock Analysis and ForecastEconomic Indicators Overview & Chat With Other Investors on Daily Signals - earlytimes.in
Is Atara Biotherapeutics Inc a good long term investmentCup and Handle Formations & Budget Friendly Portfolio Growth - earlytimes.in
Mizuho Raises Price Target on Atara Biotherapeutics to $18 From $16, Keeps Outperform Rating - MarketScreener
Will Atara Biotherapeutics Inc. (AT20) stock keep high P E multiplesTrade Risk Assessment & Verified Swing Trading Watchlists - newser.com
Will Atara Biotherapeutics Inc. (AT20) stock sustain uptrend momentumJuly 2025 Opening Moves & Daily Momentum Trading Reports - newser.com
Why Atara Biotherapeutics Inc. stock could see breakout soon2025 Year in Review & Expert Verified Movement Alerts - newser.com
Atara biotherapeutics CEO Nguyen sells $38437 in stock By Investing.com - Investing.com Canada
Can machine learning forecast Atara Biotherapeutics Inc. recoveryMarket Movement Recap & Low Risk Investment Opportunities - newser.com
Is Atara Biotherapeutics Inc. (AT20) stock attractive post correctionMarket Growth Review & Weekly Market Pulse Alerts - newser.com
How Atara Biotherapeutics Inc. (AT20) stock benefits from digital adoptionJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Can Atara Biotherapeutics Inc. stock resist market sell offsTrade Volume Report & Risk Controlled Stock Pick Alerts - newser.com
Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView
Is Atara Biotherapeutics Inc. (AT20) stock nearing a technical breakout2025 Pullback Review & Long Hold Capital Preservation Tips - newser.com
아타라 (ATRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.31%
0.33%
자본화:
|
볼륨(24시간):